top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Mar 10, 2023
Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update
- Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received Health...
Mar 9, 2023
Treatment of 1st two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial
Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial -First...
Mar 5, 2023
Receipt of Increased Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval
Alpha Tau Announces Receipt of Increased Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem...
Mar 1, 2023
Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases
JERUSALEM, March 1, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
Dec 14, 2022
Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event
JERUSALEM, December 13, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the...
Nov 23, 2022
Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
JERUSALEM, November 22, 2022 - Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the...
Nov 10, 2022
Alpha Tau to Present at Upcoming November Investor Conferences
JERUSALEM, November 9, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the...
Oct 24, 2022
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society
- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the...
Sep 11, 2022
Acceptance in Major Peer-Reviewed Journals of two Landmark Pre-Clinical Studies
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and...
Sep 6, 2022
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer
JERUSALEM, September 1, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation...
bottom of page